HaemoCer Plus
Commercial- Indications
- Hemorrhage
Company intelligence / Profile preview
BioCer Entwicklungs-GmbH
Bayreuth, Bavaria, Germanybiocer-gmbh.de ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
BioCer Entwicklungs-GmbH develops and manufactures plant-based haemostatic agents and advanced surgical meshes for soft tissue replacement. Their products are CE-marked, ISO 13485 certified, and distributed in over 80 countries. The company collaborates with leading universities to innovate new biomaterial technologies for improved patient outcomes[1][2][3].
- Therapeutic areas
- OtherHematology
- Modalities
- DeviceBiomaterial-based therapy (plant-based haemostatic materials)Surgical mesh (implantable device)
- Industry
- Surgical Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on BioCer Entwicklungs-GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCer Entwicklungs-GmbH.